Union Korea Pharm Co., Ltd. (KOSDAQ:080720)
South Korea
· Delayed Price · Currency is KRW 2,725.00
-310.00 (-10.21%)
At close: Oct 11, 2024
Union Korea Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 36,378 | 51,280 | 63,169 | 61,293 | 48,304 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 36,378 | 51,280 | 63,169 | 61,293 | 48,304 | Upgrade
|
| Revenue Growth (YoY) | -29.06% | -18.82% | 3.06% | 26.89% | -4.12% | Upgrade
|
| Cost of Revenue | 28,619 | 37,156 | 42,388 | 37,377 | 33,154 | Upgrade
|
| Gross Profit | 7,759 | 14,124 | 20,781 | 23,917 | 15,150 | Upgrade
|
| Selling, General & Admin | 15,801 | 27,632 | 24,675 | 22,147 | 23,987 | Upgrade
|
| Research & Development | 812.4 | 1,027 | 833.33 | 922.15 | 2,451 | Upgrade
|
| Amortization of Goodwill & Intangibles | 55 | 301.46 | 311.24 | 350.72 | 368.82 | Upgrade
|
| Other Operating Expenses | 232.79 | 264.02 | 244.29 | 294.22 | 196.45 | Upgrade
|
| Operating Expenses | 31,085 | 32,778 | 35,463 | 22,646 | 25,764 | Upgrade
|
| Operating Income | -23,326 | -18,654 | -14,682 | 1,271 | -10,615 | Upgrade
|
| Interest Expense | -3,243 | -3,920 | -4,112 | -2,843 | -2,229 | Upgrade
|
| Interest & Investment Income | 27.29 | 97.74 | 105.43 | 47.61 | 46.64 | Upgrade
|
| Earnings From Equity Investments | -518.08 | -23.89 | -19.46 | -5.47 | -9.49 | Upgrade
|
| Currency Exchange Gain (Loss) | -24.04 | 89.97 | 9.98 | -55.14 | 96.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -259.36 | 7,264 | 1,695 | 2,528 | -1,628 | Upgrade
|
| EBT Excluding Unusual Items | -27,343 | -15,146 | -17,004 | 943.54 | -14,338 | Upgrade
|
| Gain (Loss) on Sale of Assets | 35.25 | 0.67 | 129.04 | - | 7.54 | Upgrade
|
| Asset Writedown | - | - | - | - | -146.73 | Upgrade
|
| Other Unusual Items | -498.94 | -3,826 | 2,471 | - | - | Upgrade
|
| Pretax Income | -27,806 | -18,972 | -14,404 | 943.54 | -14,477 | Upgrade
|
| Income Tax Expense | 3,014 | 1,944 | 3,753 | 1,876 | -3,367 | Upgrade
|
| Net Income | -30,820 | -20,916 | -18,156 | -932.02 | -11,109 | Upgrade
|
| Net Income to Common | -30,820 | -20,916 | -18,156 | -932.02 | -11,109 | Upgrade
|
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 8 | Upgrade
|
| Shares Change (YoY) | 0.03% | 0.09% | -2.14% | -5.05% | 16.95% | Upgrade
|
| EPS (Basic) | -4263.00 | -2894.00 | -2514.45 | -126.31 | -1429.59 | Upgrade
|
| EPS (Diluted) | -4263.00 | -2894.00 | -2514.45 | -126.31 | -1430.00 | Upgrade
|
| Free Cash Flow | -1,230 | -529.23 | -901.15 | -8,429 | -5,254 | Upgrade
|
| Free Cash Flow Per Share | -170.11 | -73.22 | -124.80 | -1142.33 | -676.09 | Upgrade
|
| Gross Margin | 21.33% | 27.54% | 32.90% | 39.02% | 31.36% | Upgrade
|
| Operating Margin | -64.12% | -36.38% | -23.24% | 2.07% | -21.98% | Upgrade
|
| Profit Margin | -84.72% | -40.79% | -28.74% | -1.52% | -23.00% | Upgrade
|
| Free Cash Flow Margin | -3.38% | -1.03% | -1.43% | -13.75% | -10.88% | Upgrade
|
| EBITDA | -21,523 | -15,777 | -10,792 | 5,266 | -6,389 | Upgrade
|
| EBITDA Margin | -59.16% | -30.77% | -17.08% | 8.59% | -13.23% | Upgrade
|
| D&A For EBITDA | 1,803 | 2,877 | 3,890 | 3,994 | 4,226 | Upgrade
|
| EBIT | -23,326 | -18,654 | -14,682 | 1,271 | -10,615 | Upgrade
|
| EBIT Margin | -64.12% | -36.38% | -23.24% | 2.07% | -21.98% | Upgrade
|
| Effective Tax Rate | - | - | - | 198.78% | - | Upgrade
|
| Advertising Expenses | 5.29 | 302.81 | 1,984 | 865.84 | 1,090 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.